Nephros (NEPH) Liabilities from Discontinued Operations (2021 - 2022)
Nephros (NEPH) posted Liabilities from Discontinued Operations of $130000.0 for Q3 2022, up 80.56% on a QoQ basis from $72000.0 in Q4 2021.
Powered by 
Analysis
Nephros (NEPH) Liabilities from Discontinued Operations (2021 - 2022) Analysis & Trends
Nephros has reported Liabilities from Discontinued Operations for 2 years, with the latest figure at $130000.0 in Q3 2022.
- On a quarterly basis, Liabilities from Discontinued Operations changed N/A year-over-year to $130000.0 in Q3 2022; TTM through Sep 2022 was $130000.0, a N/A change from a year earlier, with the FY2021 full-year figure at $72000.0, changed N/A from the prior year.
- Liabilities from Discontinued Operations was $130000.0 for Q3 2022 at Nephros, up from $72000.0 in the prior quarter.
- The five-year high for Liabilities from Discontinued Operations was $130000.0 in Q3 2022, with the low at $72000.0 in Q4 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 178.01 Bn | 172.41 Bn | 7.27 Bn |
| 2 | Intuitive Surgical | 131.29 Bn | 126.08 Bn | 1.96 Bn |
| 3 | Medtronic | 116.38 Bn | 107.56 Bn | 6.34 Bn |
| 4 | Stryker | 106.01 Bn | 102.53 Bn | 4.50 Bn |
| 5 | Boston Scientific | 63.40 Bn | 62.86 Bn | 3.85 Bn |
| 6 | Edwards Lifesciences | 48.89 Bn | 44.64 Bn | 1.35 Bn |
| 7 | Alcon | 32.59 Bn | 31.13 Bn | 1.68 Bn |
| 8 | Dexcom | 31.84 Bn | 29.89 Bn | 830.00 Mn |
| 9 | Steris | 20.61 Bn | 20.13 Bn | 684.20 Mn |
| 10 | Nephros | 48.31 Mn | 43.62 Mn | 4.03 Mn |